Decade-Long study aims to unlock liver disease risks in HIV-Hepatitis b patients

NCT ID NCT02344680

Completed Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study follows adults in Zambia who have both HIV and chronic hepatitis B to track liver health over up to 10 years. Researchers aim to understand how current HIV treatments affect hepatitis B and liver damage, and to identify factors that lead to serious outcomes like liver cancer. The findings could help design future studies aimed at curing hepatitis B.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-HIV Agents (antiretroviral therapy)
What this could lead to: If successful, this research could identify key risk factors for liver cancer and help design future studies for a hepatitis B cure.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly improve health. Results may take years and might not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOLIC HEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS alcoholic hepatitis cirrhosis of liver fibrotic liver disease hepatitis B virus infection hepatitis D virus infection hepatocellular carcinoma HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOLIC HEPATITIS CIRRHOSIS, LIVER FIBROSIS, LIVER HBV HEPATITIS DELTA VIRUS HEPATOCELLULAR CARCINOMA HUMAN IMMUNODEFICIENCY VIRUS

Contacts and locations

Locations

Centre for Infectious Disease Research in Zambia (CIDRZ)

Lusaka, Lusaka Province, 34681, Zambia

More trials for these conditions

Other studies related to the condition(s) this trial covers.